Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

189 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel.
Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, Dalgard O, Dillion JF, Flisiak R, Forns X, Frankova S, Goldis A, Goulis I, Halota W, Hunyady B, Lagging M, Largen A, Makara M, Manolakopoulos S, Marcellin P, Marinho RT, Pol S, Poynard T, Puoti M, Sagalova O, Sibbel S, Simon K, Wallace C, Young K, Yurdaydin C, Zuckerman E, Negro F, Zeuzem S. Cornberg M, et al. Among authors: yurdaydin c. Liver Int. 2011 Jul;31 Suppl 2:30-60. doi: 10.1111/j.1478-3231.2011.02539.x. Liver Int. 2011. PMID: 21651702 Review.
Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients.
Bozdayi AM, Aslan N, Bozdayi G, Türkyilmaz AR, Sengezer T, Wend U, Erkan O, Aydemir F, Zakirhodjaev S, Orucov S, Bozkaya H, Gerlich W, Karayalçin S, Yurdaydin C, Uzunalimoğlu O. Bozdayi AM, et al. Among authors: yurdaydin c. Arch Virol. 2004 Nov;149(11):2115-29. doi: 10.1007/s00705-004-0363-2. Epub 2004 Jul 15. Arch Virol. 2004. PMID: 15503201
Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis.
Zachou K, Yurdaydin C, Drebber U, Dalekos GN, Erhardt A, Cakaloglu Y, Degertekin H, Gurel S, Zeuzem S, Bozkaya H, Schlaphoff V, Dienes HP, Bock TC, Manns MP, Wedemeyer H; HIDT-1 Study Group. Zachou K, et al. Among authors: yurdaydin c. Liver Int. 2010 Mar;30(3):430-7. doi: 10.1111/j.1478-3231.2009.02140.x. Epub 2009 Oct 16. Liver Int. 2010. PMID: 19840253
Peginterferon plus adefovir versus either drug alone for hepatitis delta.
Wedemeyer H, Yurdaydìn C, Dalekos GN, Erhardt A, Çakaloğlu Y, Değertekin H, Gürel S, Zeuzem S, Zachou K, Bozkaya H, Koch A, Bock T, Dienes HP, Manns MP; HIDIT Study Group. Wedemeyer H, et al. Among authors: yurdaydin c. N Engl J Med. 2011 Jan 27;364(4):322-31. doi: 10.1056/NEJMoa0912696. N Engl J Med. 2011. PMID: 21268724 Free article. Clinical Trial.
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.
Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, Shiffman ML, Yurdaydin C, Dalgard O. Sulkowski MS, et al. Among authors: yurdaydin c. Nat Rev Gastroenterol Hepatol. 2011 Apr;8(4):212-23. doi: 10.1038/nrgastro.2011.21. Epub 2011 Mar 8. Nat Rev Gastroenterol Hepatol. 2011. PMID: 21386812 Review.
Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment.
Grabowski J, Yurdaydìn C, Zachou K, Buggisch P, Hofmann WP, Jaroszewicz J, Schlaphoff V, Manns MP, Cornberg M, Wedemeyer H; HIDIT-1 study group. Grabowski J, et al. Among authors: yurdaydin c. Liver Int. 2011 Oct;31(9):1395-405. doi: 10.1111/j.1478-3231.2011.02593.x. Epub 2011 Jul 15. Liver Int. 2011. PMID: 21762356 Clinical Trial.
Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-α2a treatment.
Mederacke I, Yurdaydin C, Dalekos GN, Bremer B, Erhardt A, Cakaloglu Y, Yalcin K, Gurel S, Zeuzem S, Zachou K, Bozkaya H, Dienes HP, Manns MP, Wedemeyer H; Hep-Net/International Delta Hepatitis Study Group. Mederacke I, et al. Among authors: yurdaydin c. Antivir Ther. 2012;17(2):305-12. doi: 10.3851/IMP1926. Epub 2011 Oct 24. Antivir Ther. 2012. PMID: 22293066
Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection.
Mederacke I, Yurdaydin C, Großhennig A, Erhardt A, Cakaloglu Y, Yalcin K, Gurel S, Zeuzem S, Zachou K, Chatzikyrkou C, Bozkaya H, Dalekos GN, Manns MP, Wedemeyer H; Hep-Net/International Delta Hepatitis Study Group. Mederacke I, et al. Among authors: yurdaydin c. J Viral Hepat. 2012 Jun;19(6):387-95. doi: 10.1111/j.1365-2893.2011.01560.x. Epub 2011 Dec 19. J Viral Hepat. 2012. PMID: 22571900 Clinical Trial.
HBeAg-positive hepatitis delta: virological patterns and clinical long-term outcome.
Heidrich B, Serrano BC, Idilman R, Kabaçam G, Bremer B, Raupach R, Önder FO, Deterding K, Zacher BJ, Taranta A, Bozkaya H, Zachou K, Tillmann HL, Bozdayi AM, Manns MP, Yurdaydın C, Wedemeyer H. Heidrich B, et al. Among authors: yurdaydin c. Liver Int. 2012 Oct;32(9):1415-25. doi: 10.1111/j.1478-3231.2012.02831.x. Epub 2012 Jun 20. Liver Int. 2012. PMID: 22716112
189 results